News
-
Oragenics announced that it has submitted an Investigator’s Brochure application to Australian authorities seeking the go-ahead for a Phase 2 trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain… Read more . . .
-
Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in… Read more . . .
-
Tiziana Life Sciences announced that it has submitted an IND to the FDA seeking approval for a Phase 2 trial of intranasal foralumab in patients with amyotrophic lateral sclerosis. In November 2024, the company announced… Read more . . .
-
According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU’s Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study… Read more . . .
-
Taipei-based inhaled drug developer Asia Scientific Global announced that it has completed a pre-IND meeting with the US FDA regarding its Beta 1 dry powder inhaler, a PDE-5 inhibitor that the company is developing for… Read more . . .
-
BiomX announced that it has raised approximately $12 million from investors including the Cystic Fibrosis Foundation to fund a Phase 2b study of its BX004 inhaled phage cocktail for the treatment of P. aeruginosa lung… Read more . . .
-
According to Silo Pharma, the US Patent and Trademark Office (USPTO) has indicated that it will issue a new patent on March 4, 2025 that will provide protection for Silo’s SPC-15 intranasal ketamine. The company… Read more . . .
-
Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana’s intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development… Read more . . .
-
A group comprised of Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium, and CDMO OXB, has announced the initiation of the Phase 1/2 Lenticlair 1 study of BI 3720931, an inhaled lentiviral vector-based gene therapy… Read more . . .
-
Texas-based Zeteo Biomedical has announced the launch of two new devices for intranasal delivery of dry powders: the CygnusMR multi-dose device and the CygnusSDX single dose disposable device. In 2022, the company announced the launch… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA